Clinical Trial

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 9, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is designed to explore the efficacy and safety of Telitacicept combined with low-dose steroids for the treatment of refractory MG, and to investigate related biomarkers such as immunoglobulins, BlyS/APRIL, and AChR-Ab titers, in order to clarify whether Telitacicept can rapidly and effectively help achieve MG treatment goals and assist in steroid reduction.
Trial Details
NCT Number NCT06723548
Lead Sponsor First Affiliated Hospital of Wenzhou Medical University
Conditions Myasthenia Gravis, Autoimmune Diseases
Enrollment 30 participants
Start Date 2024-12
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-12-09